Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center

Articles by Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center

Treating Non–Small Cell Lung Cancer With an EGFR Exon 20 Insertion

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

EGFR Exon 20 Mutations in Non–Small Cell Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

Chemotherapy-TKI Combinations in Metastatic EGFR+ Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

TKI Combinations in Metastatic EGFR+ Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

Role of Adjuvant Osimertinib in Early Stage NSCLC

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

ADAURA Trial; Early Stage Non–Small Cell Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

Trending on OncLive

FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer

FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer

VIR-5500 Receives FDA Fast Track Designation in mCRPC

The OncFive: Top Oncology Articles for the Week of 10/4/2026

Iberdomide Plus Daratumumab/Dexamethasone Yields Significant PFS Benefit in R/R Myeloma